We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
DxGen Corp.

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.
03 Mar 2021 - 05 Mar 2021
Virtual Venue
06 Mar 2021 - 10 Mar 2021
Virtual Venue

Cancer-Associated T Cell Receptors Evaluated for Malignancy Detection

By LabMedica International staff writers
Posted on 31 Aug 2020
Print article
Image: De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection (Photo courtesy of UT Southwestern Medical Center).
Image: De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection (Photo courtesy of UT Southwestern Medical Center).
A key goal in oncology is diagnosing cancer early, when it is more treatable. Despite decades of progress, early diagnosis of asymptomatic patients remains a major challenge. Most methods for this involve detecting cancer cells, but a different approach, focused on the body’s immune response.

The adaptive immune system recognizes tumor antigens at an early stage to eradicate cancer cells. This process is accompanied by systemic proliferation of the tumor antigen–specific T lymphocytes. While detection of asymptomatic early-stage cancers is challenging due to small tumor size and limited somatic alterations, tracking peripheral T cell repertoire changes may provide an attractive solution to cancer diagnosis.

Medical scientists at the UT Southwestern Medical Center (Dallas, TX,USA) developed a deep learning method called DeepCAT to enable de novo prediction of cancer-associated T cell receptors (TCRs). They validated DeepCAT using cancer-specific or non-cancer TCRs obtained from multiple major histocompatibility complex I (MHC-I) multimer-sorting studies and demonstrated its prediction power for TCRs specific to cancer antigens. DeepCAT is used by applying a computational method for detecting tumor-infiltrating T cell CDR3 sequences from RNA-sequencing data from thousands of samples from The Cancer Genome Atlas.

The team applied DeepCAT to distinguish over 250 patients with cancer from over 600 healthy individuals using blood TCR sequences and observed high prediction accuracy. DeepCAT was also able to identify cancer TCRs (caTCRs) in blood samples from patients with early-stage kidney, ovarian, pancreatic, or lung cancer. The authors state that the approach does have certain limitations including the inability to determine a cancer's tissue of origin, and they note that inflammatory conditions might affect DeepCAT's performance.

The authors concluded that the cancer score is not intended to replace the current diagnostic methods at this time. Rather, future efforts should be made to explore whether the combined use of the cancer score with existing screening modalities that can improve diagnostic accuracy in patients. This work sets the stage for using the peripheral blood TCR repertoire for noninvasive cancer detection. The study was published on August 19, 2020 in the journal Science Translational Medicine.

Related Links:
UT Southwestern Medical Center

Gold Supplier
Gold Supplier
Clinical Chemistry Series
Clinical Chemistry Series
COVID-19 Anitibody Test
COVID-19 IgM/IgG Test
DPP COVID-19 IgM/IgG System

Print article


Molecular Diagnostics

view channel
Image: Micrograph of a colorectal adenocarcinoma (Photo courtesy of Wikimedia Commons)

Plasma or Urine Liquid Biopsy Tests May Guide Colorectal Cancer Treatment

A recent paper suggested that liquid biopsy examination of blood or urine could aid in evaluating the effectiveness of therapy for colorectal cancers that had begun to metastasize beyond the site of the... Read more


view channel
Image: Sysmex CN-Series automated blood coagulation analyzer (Photo courtesy of Sysmex Corporation)

Siemens and Sysmex Extend Agreement to Provide One of the Largest Portfolios of Hemostasis Testing Systems and Reagents

Siemens Healthineers (Erlangen, Germany) and Sysmex Corporation (Kobe, Japan) have renewed their long-standing global supply, distributorship, sales and service agreement for a broad portfolio of hemostasis... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.